MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

NCT01235897 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors
Tumors
Cancer

Interventions

DRUG: MK-2206
DRUG: Paclitaxel
DRUG: Trastuzumab

Sponsor

University of California, San Francisco

Collaborators

[object Object]